Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Cash & Equivalents (2020 - 2026)

Lucid Diagnostics filings provide 6 years of Cash & Equivalents readings, the most recent being $34.7 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 55.2% to $34.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.7 million, a 55.2% increase, with the full-year FY2025 number at $34.7 million, up 55.2% from a year prior.
  • Cash & Equivalents hit $34.7 million in Q4 2025 for Lucid Diagnostics, down from $47.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $53.7 million in Q4 2021 to a low of $21336.0 in Q3 2021.
  • Median Cash & Equivalents over the past 5 years was $25.1 million (2024), compared with a mean of $26.3 million.
  • The widest YoY moves for Cash & Equivalents: up 126137.35% in 2022, down 58.11% in 2022.
  • Lucid Diagnostics' Cash & Equivalents stood at $53.7 million in 2021, then tumbled by 58.11% to $22.5 million in 2022, then decreased by 15.92% to $18.9 million in 2023, then rose by 18.32% to $22.4 million in 2024, then surged by 55.2% to $34.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $34.7 million (Q4 2025), $47.3 million (Q3 2025), and $31.1 million (Q2 2025) per Business Quant data.